Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.32 |
| ▸ | PDE4A | P27815 | 3/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920525 | 0.88 | KDM4E (0.41) | KDM4EATML3MBTL1 | |
| SCHEMBL9920566 | 0.88 | KDM4E (0.41) | KDM4EATML3MBTL1 | |
| SCHEMBL9920542 | 0.87 | KDM4E (0.31) | KDM4EATML3MBTL1 | |
| SCHEMBL9920539 | 0.84 | KDM4E (0.37) | KDM4EATML3MBTL1 | |
| SCHEMBL19837792 | 0.83 | KDM4E (0.46) | FEN1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL9968164 | 0.83 | KDM4E (0.46) | FEN1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL9920570 | 0.83 | KDM4E (0.43) | KDM4EATML3MBTL1 | |
| SCHEMBL9920555 | 0.82 | MAOA (0.37) | KDM4EATML3MBTL1 | |
| SCHEMBL9920574 | 0.82 | CDK4 (0.37) | KDM4EATML3MBTL1 | |
| SCHEMBL12219147 | 0.82 | KDM4E (0.36) | KDM4EATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170025626-A1 | Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS | UDC IRELAND LTD (IE) | 2017-01-26 | — | — | US | disclosed |
| US-9487548-B2 | Metal complexes comprising diazabenzimidazolocarbene ligands and the use thereof in OLEDs | UDC IRELAND LIMITED (IE) | 2016-11-08 | — | — | US | disclosed |
| US-9458182-B2 | Silyl- and heteroatom-substituted compounds selected from carbazoles, dibenzofurans, dibenzothiophenes and dibenzophospholes, and use thereof in organic electronics | BASF SE (DE) | 2016-10-04 | — | — | US | disclosed |
| US-8691401-B2 | Bridged benzimidazole-carbene complexes and use thereof in OLEDS | BASF SE (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20130032766-A1 | METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOLOCARBENE LIGANDS AND THE USE THEREOF IN OLEDS | BASF SE (DE) | 2013-02-07 | — | — | US | disclosed |
| US-8362246-B2 | Bispyrimidines for electronic applications | BASF SE (DE) | 2013-01-29 | — | — | US | disclosed |
| US-20120149904-A1 | BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120012821-A1 | SILYL- AND HETEROATOM-SUBSTITUTED COMPOUNDS SELECTED FROM CARBAZOLES, DIBENZOFURANS, DIBENZOTHIOPHENES AND DIBENZOPHOSPHOLES, AND USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20110253988-A1 | BRIDGED BENZIMIDAZOLE-CARBENE COMPLEXES AND USE THEREOF IN OLEDS | BASF SE (DE) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149904-A1 | BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS | DPYD, TYMP, TYMS | FEN1 51/4885PDE4B 2425/4885PDE4A 2667/4885 |
| US-20130032766-A1 | METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOLOCARBENE LIGANDS AND THE USE THEREOF IN OLEDS | OCIAD1, OCIAD2, DRD2 | FEN1 4058/4885PDE4B 4578/4885PDE4A 4427/4885 |
| US-20110253988-A1 | BRIDGED BENZIMIDAZOLE-CARBENE COMPLEXES AND USE THEREOF IN OLEDS | CCND1, DRD2, CCND2 | FEN1 4448/4885PDE4B 4283/4885PDE4A 4484/4885 |
| US-20170025626-A1 | Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS | OCIAD1, OCIAD2, DRD2 | FEN1 4139/4885PDE4B 4560/4885PDE4A 4461/4885 |
| US-20120012821-A1 | SILYL- AND HETEROATOM-SUBSTITUTED COMPOUNDS SELECTED FROM CARBAZOLES, DIBENZOFURANS, DIBENZOTHIOPHENES AND DIBENZOPHOSPHOLES, AND USE THEREOF IN ORGANIC ELECTRONICS | DDT, CDKL1, CDK2 | FEN1 4135/4885PDE4B 4434/4885PDE4A 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.